■肝细胞癌(HCC)最有效的临床治疗方法是手术,但是大多数患者在疾病进展时被诊断出来。
■研究PD-L1抑制剂靶向治疗肝癌患者的长期预后和临床疗效。
2019年12月至2022年4月我院收治的96例晚期HCC患者,经过回顾性分析后,根据治疗方案分为两组:对照组43例患者接受以索拉非尼为基础的靶向治疗,而观察组53例患者采用了dulvalizumab治疗。观察指标用于评估肝癌患者接受达瓦珠单抗靶向治疗的临床疗效和长期预后。其中包括疾病控制率,肿瘤标志物,免疫功能,生存,生存质量,以及血小板减少等不良副作用的发生,白细胞减少症,呕吐,和皮疹。
■最初的KPS分数,CEA,CA199,AFP,CD3+,CD4+,CD4+/CD8+,IgG,IgM,两组间IgA水平差异无统计学意义(P>0.05)。治疗后,观察组患者的疾病控制率明显高于对照组(92.45%vs.74.42%)和提高的KPS评分,操作系统,PFS,CD3+,CD4+,CD4+/CD8+,IgG,IgM,和IgA水平与对照组相比。此外,观察组CEA显著降低,CA199和AFP水平,不良反应的总体发生率较低(16.98%vs.51.16%)与对照组比较(P<0.05)。
■在PD-L1抑制剂中,dulvalizumab靶向治疗HCC的临床疗效较好,增强疾病的控制能力,大大降低患者的肿瘤标志物水平。这大大增强了患者的免疫系统,延长他们的生命,提高他们的生存质量。负面反应的频率是最小和安全的。
UNASSIGNED: The most effective clinical treatment for hepatocellular carcinoma (HCC) is surgery, but most patients are diagnosed when the disease has progressed.
UNASSIGNED: To examine the long-term prognosis and clinical effectiveness of PD-L1 inhibitor-targeted therapy for patients suffering from HCC.
UNASSIGNED: Ninety-six patients with advanced HCC who were admitted to our hospital between December 2019 and April 2022 were split into two groups based on the treatment plan after a retrospective analysis: 43 patients in the control group underwent sorafenib-based targeted therapy, while dulvalizumab was used to treat 53 patients in the observation group. Observation indexes were used to assess the clinical effectiveness and long-term prognosis of HCC patients receiving targeted therapy with dulvalizumab, which included the disease control rate, tumor markers, immune function, survival, quality of survival, and the occurrence of unfavorable side effects such as thrombocytopenia, leukopenia, vomiting, and rash.
UNASSIGNED: The initial KPS scores, CEA, CA199, AFP, CD3+, CD4+, CD4+/CD8+, IgG, IgM, and IgA levels did not differ significantly between the two groups (P> 0.05). After treatment, the observation group showed a significantly higher disease control rate (92.45% vs. 74.42%) and improved KPS score, OS, PFS, CD3+, CD4+, CD4+/CD8+, IgG, IgM, and IgA levels compared to the control group. Additionally, the observation group exhibited significantly reduced CEA, CA199, and AFP levels, and a lower overall incidence of adverse reactions (16.98% vs. 51.16%) compared to the control group (P< 0.05).
UNASSIGNED: The clinical efficacy of dulvalizumab-targeted treatment of HCC among PD-L1 inhibitors is better, enhancing the disease\'s ability to be controlled considerably lowering patients\' levels of tumor markers. This greatly boosts patients\' immune systems, extends their lives and improves the quality of their survival. The frequency of negative reactions is minimal and safe.